In ovarian cancer, upregulation of MGAT5 could also exacerbate resistance to anti-PD-L1 immunotherapy by catalyzing branched N-glycans, which enhanced its binding with PD-1 on CD8+ T cells (67). Here, CD8A is linked to ovarian cancer.